194 related articles for article (PubMed ID: 27496805)
1. Peroxisome proliferator-activated receptor α-dependent renoprotection of murine kidney by irbesartan.
Harada M; Kamijo Y; Nakajima T; Hashimoto K; Yamada Y; Shimojo H; Gonzalez FJ; Aoyama T
Clin Sci (Lond); 2016 Nov; 130(21):1969-1981. PubMed ID: 27496805
[TBL] [Abstract][Full Text] [Related]
2. Huangkui capsule, an extract from Abelmoschus manihot (L.) medic, improves diabetic nephropathy via activating peroxisome proliferator-activated receptor (PPAR)-α/γ and attenuating endoplasmic reticulum stress in rats.
Ge J; Miao JJ; Sun XY; Yu JY
J Ethnopharmacol; 2016 Aug; 189():238-49. PubMed ID: 27224243
[TBL] [Abstract][Full Text] [Related]
3. Interactions of PPAR α and GLUT4 in DOCA/salt-induced renal injury in mice.
Ighodaro I; Eric OK; Adebayo O
Niger J Physiol Sci; 2013 Dec; 28(2):127-33. PubMed ID: 24937386
[TBL] [Abstract][Full Text] [Related]
4. Cardiac and renal protective effects of irbesartan via peroxisome proliferator-activated receptorγ-hepatocyte growth factor pathway independent of angiotensin II Type 1a receptor blockade in mouse model of salt-sensitive hypertension.
Kusunoki H; Taniyama Y; Rakugi H; Morishita R
J Am Heart Assoc; 2013 Apr; 2(2):e000103. PubMed ID: 23608606
[TBL] [Abstract][Full Text] [Related]
5. Fenofibrate, a PPARα agonist, has renoprotective effects in mice by enhancing renal lipolysis.
Tanaka Y; Kume S; Araki S; Isshiki K; Chin-Kanasaki M; Sakaguchi M; Sugimoto T; Koya D; Haneda M; Kashiwagi A; Maegawa H; Uzu T
Kidney Int; 2011 Apr; 79(8):871-82. PubMed ID: 21270762
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of irbesartan are not altered in special populations.
Marino MR; Vachharajani NN
J Cardiovasc Pharmacol; 2002 Jul; 40(1):112-22. PubMed ID: 12072584
[TBL] [Abstract][Full Text] [Related]
7. Pretreatment by low-dose fibrates protects against acute free fatty acid-induced renal tubule toxicity by counteracting PPARα deterioration.
Takahashi K; Kamijo Y; Hora K; Hashimoto K; Higuchi M; Nakajima T; Ehara T; Shigematsu H; Gonzalez FJ; Aoyama T
Toxicol Appl Pharmacol; 2011 May; 252(3):237-49. PubMed ID: 21338618
[TBL] [Abstract][Full Text] [Related]
8. Irbesartan treatment up-regulates hepatic expression of PPARalpha and its target genes in obese Koletsky (fa(k)/fa(k)) rats: a link to amelioration of hypertriglyceridaemia.
Rong X; Li Y; Ebihara K; Zhao M; Kusakabe T; Tomita T; Murray M; Nakao K
Br J Pharmacol; 2010 Aug; 160(7):1796-807. PubMed ID: 20649581
[TBL] [Abstract][Full Text] [Related]
9. Alleviative effect of fucoxanthin-containing extract from brown seaweed Laminaria japonica on renal tubular cell apoptosis through upregulating Na
Chen YC; Cheng CY; Liu CT; Sue YM; Chen TH; Hsu YH; Hwang PA; Chen CH
J Ethnopharmacol; 2018 Oct; 224():391-399. PubMed ID: 29920359
[TBL] [Abstract][Full Text] [Related]
10. Interaction between irbesartan, peroxisome proliferator-activated receptor (PPAR-γ), and adiponectin in the regulation of blood pressure and renal function in spontaneously hypertensive rats.
Afzal S; Sattar MA; Johns EJ; Abdulla MH; Akhtar S; Hashmi F; Abdullah NA
J Physiol Biochem; 2016 Dec; 72(4):593-604. PubMed ID: 27405250
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic effects of angiotensin II type 1 receptor blocker, irbesartan, on non-alcoholic steatohepatitis using FLS-ob/ob male mice.
Kato J; Koda M; Kishina M; Tokunaga S; Matono T; Sugihara T; Ueki M; Murawaki Y
Int J Mol Med; 2012 Jul; 30(1):107-13. PubMed ID: 22469867
[TBL] [Abstract][Full Text] [Related]
12. Elafibranor Inhibits Chronic Kidney Disease Progression in NASH Mice.
Tsai HC; Chang FP; Li TH; Liu CW; Huang CC; Huang SF; Yang YY; Lee KC; Hsieh YC; Wang YW; Lee TY; Huang YH; Hou MC; Lin HC
Biomed Res Int; 2019; 2019():6740616. PubMed ID: 31321239
[TBL] [Abstract][Full Text] [Related]
13. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
Lewis EJ; Lewis JB
Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
[TBL] [Abstract][Full Text] [Related]
14. Peroxisome proliferator-activated receptor α attenuates high-cholesterol diet-induced toxicity and pro-thrombotic effects in mice.
Lu Y; Harada M; Kamijo Y; Nakajima T; Tanaka N; Sugiyama E; Kyogashima M; Gonzalez FJ; Aoyama T
Arch Toxicol; 2019 Jan; 93(1):149-161. PubMed ID: 30341732
[TBL] [Abstract][Full Text] [Related]
15. Expression of renin-angiotensin system and peroxisome proliferator-activated receptors in alcoholic cardiomyopathy.
Jing L; Li WM; Zhou LJ; Li S; Kou JJ; Song J
Alcohol Clin Exp Res; 2008 Nov; 32(11):1999-2007. PubMed ID: 18783396
[TBL] [Abstract][Full Text] [Related]
16. Interaction of PPARα With the Canonic Wnt Pathway in the Regulation of Renal Fibrosis.
Cheng R; Ding L; He X; Takahashi Y; Ma JX
Diabetes; 2016 Dec; 65(12):3730-3743. PubMed ID: 27543085
[TBL] [Abstract][Full Text] [Related]
17. Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor alpha.
Park CW; Kim HW; Ko SH; Chung HW; Lim SW; Yang CW; Chang YS; Sugawara A; Guan Y; Breyer MD
Diabetes; 2006 Apr; 55(4):885-93. PubMed ID: 16567507
[TBL] [Abstract][Full Text] [Related]
18. NAD(P)H oxidase/nitric oxide interactions in peroxisome proliferator activated receptor (PPAR)alpha-mediated cardiovascular effects.
Newaz M; Blanton A; Fidelis P; Oyekan A
Mutat Res; 2005 Nov; 579(1-2):163-71. PubMed ID: 16054168
[TBL] [Abstract][Full Text] [Related]
19. Decreased longevity and enhancement of age-dependent lesions in mice lacking the nuclear receptor peroxisome proliferator-activated receptor alpha (PPARalpha).
Howroyd P; Swanson C; Dunn C; Cattley RC; Corton JC
Toxicol Pathol; 2004; 32(5):591-9. PubMed ID: 15603543
[TBL] [Abstract][Full Text] [Related]
20. Periostin contributes to renal and cardiac dysfunction in rats with chronic kidney disease: Reduction of PPARα.
Bian X; Su X; Wang Y; Zhao G; Zhang B; Li D
Biochimie; 2019 May; 160():172-182. PubMed ID: 30890453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
